TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21614530

Group type: EXPERIMENTAL
Intervention: Box isolation method
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional circumferential pulmonary vein isolation (PVI)
Number of subjects: 29
Study: 19222688

Group type: EXPERIMENTAL
Intervention: Pediatric Forensic Nurse Examiner (FNE) program; n=95
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-FNE medical professionals; n=54
Number of subjects: 149
Study: 17721102

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention programme
Number of subjects: 9645

Group type: COMPARATOR
Intervention: Standard activities
Number of subjects: 9645
Study: 15053240

Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study: 11350463

Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg orally
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo orally
Number of subjects: 150
Study: 9883919

Group type: EXPERIMENTAL
Intervention: Gestational diabetes group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Acetylcholine induced vasodilatation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 8140175

Group type: EXPERIMENTAL
Intervention: Type A group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Type B group
Number of subjects: 21
Study: 2686713

Group type: EXPERIMENTAL
Intervention: Zofenopril (ZOF), 30 mg, once daily (n = 18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT), 25 mg, once daily (n = 19)
Number of subjects: 37
Study: 7976

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam IV drip
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam IV bolus
Number of subjects: 0
Study: 31006801

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 152
Study: 28731925

Group type: EXPERIMENTAL
Intervention: ThPVB with 0.5% bupivacaine combined with general anaesthesia
Number of subjects: 68

Group type: COMPARATOR
Intervention: General anaesthesia only
Number of subjects: 68
Study: 25421934

Group type: EXPERIMENTAL
Intervention: Barbed suture (Quill™)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-barbed sutures
Number of subjects: 64
Study: 23549581

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily (initially 30 mg for 1 week, then 60 mg for 4 weeks)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 21799214

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g/kg BM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine + Sodium bicarbonate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18645344

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT) with 0.9% saline solution infusion
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Leptin and NO evaluated together
Number of subjects: 43
Study: 16437735

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine regimen (Sang Ju Yin and Yu Ping Feng San) taken orally for 14 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control study without TCM treatment
Number of subjects: 37
Study: 12629532

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10711928

Group type: EXPERIMENTAL
Intervention: Aerosol Edmonston‐Zagreb vaccine
Number of subjects: 4327

Group type: COMPARATOR
Intervention: Subcutaneous Edmonston‐Zagreb vaccine
Number of subjects: 4327

Group type: COMPARATOR
Intervention: Subcutaneous Schwarz vaccine
Number of subjects: 4327

Group type: COMPARATOR
Intervention: Aerosol Schwarz vaccine
Number of subjects: 4327
Study: 9180629

Group type: EXPERIMENTAL
Intervention: Oral alcohol intake (1.0 g/kg body wt)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 16
Study: 8256930

Group type: EXPERIMENTAL
Intervention: Empiric antimicrobials received
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Patients with resolution of intra-abdominal infection
Number of subjects: 175

Group type: COMPARATOR
Intervention: Patients with postoperative infectious complications
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Average age
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Admission WBC
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Diagnosis of acute appendicitis
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Intraoperative isolate resistance, age, and admission WBC
Number of subjects: 175
Study: 2939253

Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 34
Study: 30624594

Group type: EXPERIMENTAL
Intervention: Lactotripeptide (LTP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LTP with exercise
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LTP without exercise
Number of subjects: 64
Study: 29437573

Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity exercise group in STRRIDE-PD
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 20 kcal/kg per week exercise group in E-MECHANIC
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 8 kcal/kg per week exercise group in E-MECHANIC
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group in E-MECHANIC
Number of subjects: 196
Study: 27737361

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (Infrared laser, AsGaAI, wavelength of 790 nm, output power of 20 mW, fluence of 6 J/cm2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 24587233

Group type: EXPERIMENTAL
Intervention: unguided online self-help
Number of subjects: 236

Group type: COMPARATOR
Intervention: waitlist control group
Number of subjects: 236
Study: 21729372

Group type: EXPERIMENTAL
Intervention: Energy-protein supplementation (one or six biscuits daily for 60 days)
Number of subjects: 377
Study: 20134330

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 800/200 mg QD
Number of subjects: 599

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg BID
Number of subjects: 599
Study: 17295566

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Combined MI and coping skills training (MI + CBT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-help-seeking group (NHS)
Number of subjects: 198
Study: 15005868

Group type: EXPERIMENTAL
Intervention: Matrix-tapping task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random-interval generation task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-interval generation task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression
Number of subjects: 0
Study: 11298162

Group type: EXPERIMENTAL
Intervention: Lignocaine and phenylephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lignocaine alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 100

Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 100
Study: 9555757

Group type: EXPERIMENTAL
Intervention: Montelukast (5-mg chewable tablet) once daily at bedtime for 8 weeks
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo once daily at bedtime for 8 weeks
Number of subjects: 336
Study: 7936950

Group type: EXPERIMENTAL
Intervention: High amount of gaze
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low amount of gaze
Number of subjects: 64
Study: 3348323

Group type: EXPERIMENTAL
Intervention: 12 hours of ejaculatory abstinence
Number of subjects: 10

Group type: COMPARATOR
Intervention: 120 hours of ejaculatory abstinence
Number of subjects: 10
Study: 28734948

Group type: EXPERIMENTAL
Intervention: Flipped classroom approach
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional classroom
Number of subjects: 59
Study: 28509904

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy emphasizing exercise during behavioral activation (CBT-E)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy with pleasurable low-energy activities (CBT-C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Passive waiting list control group (WL)
Number of subjects: 98
Study: 26267119

Group type: EXPERIMENTAL
Intervention: Nestorone® (NES) and ethinyl estradiol (EE) CVR
Number of subjects: 120
Study: 23937669

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 21167340

Group type: EXPERIMENTAL
Intervention: IRA infusion of 10 million CD34(+) cells
Number of subjects: 31

Group type: COMPARATOR
Intervention: IRA infusion of 5 million CD34(+) cells
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no CD34(+) cell infusion)
Number of subjects: 31
Study: 18198256

Group type: EXPERIMENTAL
Intervention: Withdrawal of life support
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Chart documentation of physician recommendations to withdraw life support
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Discussions of patients' wishes
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Discussions of families' spiritual needs
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Spiritual care involvement
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Expressions of families' wishes to withdraw life support
Number of subjects: 356
Study: 17036488

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 70
Study: 14623799

Group type: EXPERIMENTAL
Intervention: Electroanatomic approach (71 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Circular mapping (537 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Distal isolation (25 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Ostial isolation based on PV angiography (102 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Guided by intracardiac echocardiography (140 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Energy delivery based on visualization of microbubbles (270 patients)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Mild and moderate narrowing
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: V/Q scans
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Mild narrowing 3 months after ablation
Number of subjects: 608
Study: 10828934

Group type: EXPERIMENTAL
Intervention: Multinutrient liquid supplement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-nutritive placebo drink
Number of subjects: 50
Study: 9344052

Group type: EXPERIMENTAL
Intervention: Shunted hydrocephalus
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Arrested hydrocephalus
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: No hydrocephalus
Number of subjects: 88

Group type: COMPARATOR
Intervention: Term comparison group
Number of subjects: 88
Study: 1586984

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) 200 mg/m2 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) 200 mg/m2 in combination with recombinant human TNF-alpha (rhTNF alpha) 88 micrograms/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carmustine (BCNU) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carmustine (BCNU) in combination with TNF
Number of subjects: 0
Study: 4051334

Group type: EXPERIMENTAL
Intervention: IV cefamandole
Number of subjects: 105

Group type: COMPARATOR
Intervention: IV carbenicillin
Number of subjects: 105
Study: 30736858

Group type: EXPERIMENTAL
Intervention: Checkpoint blockade based immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RECIST-based efficacy metric
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite response rate
Number of subjects: 0
Study: 29338751

Group type: EXPERIMENTAL
Intervention: E-course program (12 sessions + 2 booster sessions)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional didactic drug prevention course (2 sessions)
Number of subjects: 84
Study: 26547890

Group type: EXPERIMENTAL
Intervention: Ultrasonic circular cyclocoagulation procedure
Number of subjects: 30
Study: 26773120

Group type: EXPERIMENTAL
Intervention: BML-positive individuals (BML grade ≥ 2)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Overall population (including BML-positive and BML-negative)
Number of subjects: 559
Study: 22585378

Group type: EXPERIMENTAL
Intervention: 5-day course of oral prednisolone
Number of subjects: 198
Study: 20631323

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long-chain (n-3) PUFA
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (high-oleic sunflower-seed oil)
Number of subjects: 0
Study: 18356189

Group type: EXPERIMENTAL
Intervention: Active-Passive Bilateral Therapy (APBT) for 10-15 min prior to self-directed motor practice
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active-Passive Bilateral Therapy (APBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Self-directed motor practice (control group)
Number of subjects: 32
Study: 15743471

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg subcutaneously every other week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control individuals (healthy individuals, N=20)
Number of subjects: 10
Study: 12487388

Group type: EXPERIMENTAL
Intervention: Saquinavir SGC 1200 mg three-times daily plus two NRTIs (arm A)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Saquinavir SGC 1600 mg twice-daily plus two NRTIs (arm B)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily plus a single NRTI (arm C)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Saquinavir SGC 1600 mg twice-daily (arm B)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily (arm C)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Saquinavir SGC 1200 mg three-times daily (arm A)
Number of subjects: 837
Study: 10588092

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 0
Study: 7783096

Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verapamil SR plus Enalapril
Number of subjects: 20
Study: 1958993

Group type: EXPERIMENTAL
Intervention: Polymorphonuclear elastase test
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual prognostic systems (Ranson and Osborne)
Number of subjects: 182
Study: 6085365

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20-40 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxprenolol (160-320 mg/day)
Number of subjects: 60
Study: 31381365

Group type: EXPERIMENTAL
Intervention: Competency-Based Approaches to Community Health (COACH) intervention, consisting of 15 weekly, 90-minute sessions followed by 3 months of twice-monthly health coaching calls.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group receiving a twice-monthly school readiness curriculum for 3 months.
Number of subjects: 117
Study: 28669110

Group type: EXPERIMENTAL
Intervention: NDE-positive group (3% of participants)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: NDE-positive group
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Theistic religions (Christianity, Islam, Hinduism)
Number of subjects: 826
Study: 26753844

Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 99
Study: 25252515

Group type: EXPERIMENTAL
Intervention: Structured behavioural management and pharmacological treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 90
Study: 22372512

Group type: EXPERIMENTAL
Intervention: 10 mg molindone (5 mg if weight <30 kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 20 mg molindone (10 mg if weight <30 kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 30 mg molindone (15 mg if weight <30 kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 40 mg molindone (20 mg if weight <30 kg)
Number of subjects: 78
Study: 20485133

Group type: EXPERIMENTAL
Intervention: Preoperative warm-up using a virtual reality simulator
Number of subjects: 8

Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 8
Study: 18271234

Group type: EXPERIMENTAL
Intervention: Acupuncture at Dazhui (GV 14) and Shenque (CV 8)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Western medicine (Haloperidol orally)
Number of subjects: 68
Study: 16898430

Group type: EXPERIMENTAL
Intervention: OASIS Moisturizing Mouthwash
Number of subjects: 49

Group type: COMPARATOR
Intervention: Experimental mouthwash formulation
Number of subjects: 49
Study: 15255163

Group type: EXPERIMENTAL
Intervention: Irinotecan and cisplatin (IP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan, cisplatin, and etoposide (IPE) administered every 4 weeks (arm B)
Number of subjects: 0
Study: 10716459

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 8959290

Group type: EXPERIMENTAL
Intervention: Ventricular abnormality (VA group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal CT findings (NCT group)
Number of subjects: 56
Study: 1382003

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 8
Study: 3158320

Group type: EXPERIMENTAL
Intervention: Desogestrel + ethinylestradiol (150 micrograms/30 micrograms; Marvelon)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Levonorgestrel + ethinylestradiol (150 micrograms/30 micrograms)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Triphasic preparation containing levonorgestrel + ethinylestradiol
Number of subjects: 78
Study: 31859087

Group type: EXPERIMENTAL
Intervention: Collagen-based supplement (1000 kcal)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 31
Study: 29764693

Group type: EXPERIMENTAL
Intervention: Highest quintile of dietary vitamin B6 intake (men)
Number of subjects: 134480

Group type: EXPERIMENTAL
Intervention: Highest quintile of dietary vitamin B6 intake (women)
Number of subjects: 134480

Group type: COMPARATOR
Intervention: Lowest quintile of dietary vitamin B6 intake (women)
Number of subjects: 134480
Study: 28106331

Group type: EXPERIMENTAL
Intervention: High-dose antivenom (20 vials)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Low-dose antivenom (10 vials) plus 4 U of fresh frozen plasma (FFP)
Number of subjects: 141
Study: 25929712

Group type: EXPERIMENTAL
Intervention: Isolated extraction of mandibular teeth (second premolars or first molars)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (standard therapies)
Number of subjects: 25
Study: 23475128

Group type: EXPERIMENTAL
Intervention: 4,000 IU vitamin D (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 45
Study: 21216833

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1464
Study: 18645050

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow-release, once daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 37
Study: 17074656

Group type: EXPERIMENTAL
Intervention: FEC50 (fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2), 6 cycles every 21 days)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control (no systemic treatment)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: FEC50
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control
Number of subjects: 328
Study: 14570789

Group type: EXPERIMENTAL
Intervention: Airway Management Device (AMD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: classic Laryngeal Mask Airway (cLMA)
Number of subjects: 100
Study: 10993030

Group type: COMPARATOR
Intervention: 17beta-estradiol 1 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: 17beta-estradiol 0.5 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 8822775

Group type: EXPERIMENTAL
Intervention: Training for primary health care workers (PHCWs)
Number of subjects: 0
Study: 1580773

Group type: EXPERIMENTAL
Intervention: Flex Foot
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Seattle Foot
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both prostheses
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 3909321

Group type: EXPERIMENTAL
Intervention: Intravenous aztreonam (1-2 g every 8 hr)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous tobramycin (3-5 mg/kg per day)
Number of subjects: 49
Study: 30609986

Group type: EXPERIMENTAL
Intervention: Game‐Motivated ePRO
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ePRO
Number of subjects: 197

Group type: COMPARATOR
Intervention: Paper PRO
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Average diary completion time
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: System Usability Scale score
Number of subjects: 197